Skip to main content

Timothy Voorhees, MD

Instructor, Division of Hematology

Education

Undergraduate: University of Michigan
Medical School: The Ohio State University College of Medicine
Residency: The Ohio State University Wexner Medical Center

Research and Career Path

Timothy Voorhees has a clinical interest in malignant hematology, specifically lymphomas. He has a research interest in Chimeric Antigen Receptor (CAR) T-cell therapies and rare lymphomas. He plans to develop a career in early-phase, translational clinical trial development focused on cellular therapies.

Training During Fellowship

  • Duke-UNC Immunotherapy T32 – (August 2019-Present)
  • Master of Science in Clinical Research – (August 2019-Present)

Awards

  • 2019 ASCO/AACR Methods in Clinical Cancer Research Workshop (Vail, CO)
  • 2019 NCOA Outstanding Fellow Award
  • Lineberger Clinical Pilot Award ($50K)
  • 2019 ASH Abstract Achievement Award
  • 2020 ASCO Young Investigator Award
  • 2020 AACR-AstraZeneca Lymphoma Research Fellowship

Publications

Lindsey E. Roeker, MD et al. “Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents”. Submitted to Blood. January 2020.

Anthony R. Mato, et al. “Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies”. Submitted to Clinical Cancer Research. December 2019.

Voorhees TJ, Bowers EV, Kelsey CR, Park Y, Beaven AW. “Cutaneous T-cell Lymphoma.” Novel Therapeutics for Rare Lymphomas. 2019.

Cotten SW, Shajani-Yi Z, Cervinski MA, Voorhees T, Tuchman SA, Korpi-Steiner N. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. Clin Biochem. 2018 Aug;58:100-107

Abstract Presentations

Voorhees, TJ, Ghosh, N, Dotti, G, Savoldo, B; Grover, N; Beaven, A. Long term remission in multiply relapsed enteropathy associated T-cell lymphoma type 1 following CD30 redirected chimeric antigen receptor T-cell therapy. 2020 T-cell Lymphoma Forum. La Jolla, CA. Jan 2020. Poster Session.

Voorhees, TJ, Grover NS, Beaven AW, Park SI, Morrison JK*, Cheng CJ*, Laing S*, Dotti G*, Savoldo B, Serody, JS.. “Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma”. ASH Annual Meeting. Orlando, FL. December 2019. Poster Session.

Voorhees, TJ, Grover NS, Galeotti J, Montgomery ND, Moore DT, Beaven AW, Dittus, C. “High risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder – A Single Center Experience”. ASH Annual Meeting. Orlando, FL. December 2019. Poster Session.

Victor M. Orellana-Noia, et al., “Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis”. ASH Annual Meeting. Orlando, FL. December 2019. Poster Session.

Lindsey E. Roeker, et al.  “Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents”. ASH Annual Meeting. Orlando, FL. December 2019. Poster Session.

Anthony R. Mato, et al.  “Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies”. ASH Annual Meeting. Orlando, FL. December 2019. Oral/Poster Session. 

Voorhees TJ, Grover N, Beaven A, Dotti G, Savoldo B, Serody J. “Prospective Pilot Study Of PD-1 Inhibition Following CD30 Directed CAR-T Cell Therapy In Relapsed/Refractory Hodgkin Lymphoma”. NCOA Annual Meeting. Cary, NC. September 2019. Poster Session.